RxDoctor Payments Data

Melissa Wood

Family · Easton, MDNPI 1194434480

Payments from drug & device makers

$1,279in general payments, 2019–2025

Across 45 payments — averaging $28.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$197
  • Astellas Pharma US Inc$180
  • Novo Nordisk$132
  • Vivus LLC$120
  • E.r. Squibb & Sons, L.L.C.$120
  • Daiichi Sankyo Inc.$111
  • plus $420 from 11 others

What the payments were for

  • Food & beverage$1,18993%
  • Education$907%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,279 in reported general payments places this provider in the 75th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$36,040
Medicare patients
200
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide19$23,102
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$8,985
Atorvastatin Calcium102$1,245
Levothyroxine Sodium58$746
Losartan Potassium43$534
Albuterol Sulfate HfaAlbuterol Sulfate13$439
Bupropion XlBupropion Hcl12$406
Montelukast Sodium22$393
Rosuvastatin Calcium26$325
Amlodipine Besylate41$319
Pantoprazole Sodium25$272
Metformin Hcl34$257
Lisinopril45$245
Simvastatin19$236
Omeprazole28$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$197$23,10219 claims
GSKTrelegy Ellipta$21$8,98515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,843 family providers in Maryland.

Other family in Easton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →